Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms

Obstetrics and Gynecology

Volumn 112, Issue 6, 2008, Pages 1311-1318

  Gopal, Manish ^a,b   Haynes, Kevin ^a   Bellamy, Scarlett L ^a   Arya, Lily A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLAVOXATE; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TERODILINE; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; AGE DISTRIBUTION; ANAMNESIS; ARTICLE; DATA BASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SMOKING HABIT; AGED; FACTUAL DATABASE; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; OVERACTIVE BLADDER; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; URINARY BLADDER, OVERACTIVE;

EID: 58849099645     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31818e8aa4     Document Type: Article

References (22)

1. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
2. Wein AJ, Rovner ES. Definition and epidemiology of overac-tive bladder. Urology 2002;60 suppl:7-12.
3. Thomas TM, Plymat KR, Blannin J, Meade TW. Prevalence of urinary incontinence. Br Med J 1980;281:1243-5.
4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
5. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:S580-90.
6. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propan-theline versus placebo. J Urol 1991;145:813-6.
7. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybu-tynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-9.
8. Jonas U, Hofner K, Madersbacher H, Holmdahl T. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group [published erratum appears in World J Urol 1997;15:210]. World J Urol 1997;15:144-51.
9. EPIC. EPIC GPRD: a guide for researchers. London (UK): EPIC; 2003.
10. Jick SS, Kaye JA, Vasilakis-Scaramozza Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9.
11. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001;17:1075-80.
12. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepi-demiol Drug Saf 2007;16:393-401.
13. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York (NY): John Wiley & Sons; 1999.
14. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505.
15. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11:S121-9.
16. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overac-tive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
17. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chlorine and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001;76:358-63.
18. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
19. Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. The Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003190. DOI: 10.1002/14651858. CD003190.
20. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006;24:1193-200.
21. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire J-P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005;19:607-13.
22. van Wijk BL, Avorn J, Solomon DH, Klungel OH, Heerdink ER, de Boer A, et al. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. J Hypertens 2007;25:689-97.